Objectives: To evaluate potential costs and savings from implementing an evaluation tool that uses bedside review of antibiotic use and infection management to assess whether patients with infections in acute medical and surgical wards could have their antibiotic regimen changed and be safely managed out of hospital.
Introduction
The management of infections in hospital represents a significant burden to the UK National Health Service (NHS). 1, 2 Once acute infection has been controlled, patients may be discharged into the community with no continuing antibiotic therapy, oral antibiotic therapy or intravenous (iv) infusion therapy outside the hospital. Government policy firmly supports the objective of moving care closer to home and providing an increasingly large proportion of the care pathway outside the hospital setting. 3 However, there are still thought to be significant numbers of patients who could potentially be discharged but who remain in hospital.
To evaluate the potential impact of an antibiotic management and early discharge programme on NHS resources and patient pathways in this population, a series of service evaluations was undertaken in a sample of hospital trusts/health boards across the UK. These service evaluations were exploratory studies designed to provide useful descriptive information for a sample of individual medical and surgical inpatients across a range of different practice settings. The information collected included antibiotics used, scope for changing or stopping current antibiotic therapy, suitability of patients on iv antibiotics for continuation of iv therapy either as an outpatient or outside the hospital environment if an outpatient parenteral antimicrobial therapy (OPAT) service was available, and whether discharge from hospital is recommended. Full clinical details of this study are reported in a companion paper. 4 From these and other data collected, it was possible to undertake an economic analysis to estimate the cost consequences of potential changes in antibiotic therapy, discharge dates and community support, and so provide estimates of the potential cost savings from an antibiotic management and early discharge intervention in the study population.
Methods
The service evaluation was conducted across six hospital settings in the UK: the Royal Hampshire County Hospital, Winchester; the Northern General Hospital, Sheffield; Glasgow Royal Infirmary; Imperial College NHS Trust; Guys & St Thomas's NHS Foundation Trust; and Leeds NHS Trust. Data on patient demographics and current antibiotic prescribing were collected on the day of the evaluation from the patient notes and drug charts by the service evaluation facilitator, and assessment of suitability for discharge on the day of the evaluation was made by a suitably qualified healthcare professional, acting independently from the clinical care team. Data relating to the date of actual discharge and the formal reason for admission were also collected by the service evaluation facilitator. Information was collected for each patient on age, specialty, home circumstances, presence or absence of antibiotic allergy and other salient characteristics, current antibiotic treatment(s), assessed ability to have antibiotic treatment changed or stopped, whether hospital discharge was recommended with or without community support, and whether discharge was not recommended but would have been had OPAT services been available.
Unit costs were obtained from a range of sources and are reported in Table 1 . The costs per day in different specialties were taken from NHS Trust Financial Returns 5 updated to 2008/09 prices using the NHS Hospital and Community Health Services Pay and Prices Index. 6 All antibiotic use recorded was costed using net ingredient costs as reported in the 2010 British National Formulary (BNF), 7 with any assumptions concerning doses, mode of administration and brand agreed with clinical opinion. The cost of OPAT services was taken from a UK study reported in 2009, 8 which estimated a cost of £151.80 per patient per day. Community care costs were based on an estimate of the median daily cost of delivering a package of health and social care services to a domiciliary setting. 9 The costs associated with iv administration of antibiotics in hospital were taken from a Dutch study, which included staff and material costs for pumps, bolus injections, piggyback infusions, and the insertion and removal of iv catheters. 10 Unit costs were then attached to the observed resource use volumes of each patient, and to the predicted resource use volumes if antibiotic therapy had been switched, the patient had been discharged and community support services had been provided, to obtain a cost per patient.
For the study population, mean estimates of resource volumes, costs and changes in costs were then reported, accompanied by appropriate measures of variance, for total costs and for main cost categories: antibiotics, bed-days and community support, with all 95% CIs calculated directly from the variance in the calculated costs per patient.
From these estimates, the potential cost savings arising from an antibiotic management and early discharge programme were calculated, giving an indication of the maximum costs that could be incurred in Gray et al.
providing such a programme while remaining cost neutral or yielding savings.
Results
A total of 429 patients were identified across all six hospital sites as being on antibiotics; however, in one site (Sheffield) full information was not available on the length of stay and actual discharge date of patients, and so the economic analysis was performed for the 291 patients on antibiotics in the five hospitals for which full information was available. Table 2 reports descriptive information on this population. Patients were on 30 wards, mainly in general medicine (n¼134, 46%) or general surgery (n¼91, 31%) specialties. One-hundred-and-seventy-six patients (61%) lived with family and 79 (27%) lived alone; the mean age at the assessment was 69, with 22% aged ,60 and 29% aged ≥80. Figure 1 reports full details on the results of the assessment. Of the 291 patients on antibiotics with full information available for analysis, 161 (55%) were on oral antibiotics only and 130 (45%) on iv+oral antibiotics. The assessment identified 82 patients (28%) as suitable for discharge, 54 (66%) on oral antibiotics and 28 (34%) on iv antibiotics. Four of these 82 patients would have required OPAT services to make earlier discharge feasible. The assessment indicated that 36 of the 54 on oral antibiotics (67%) could stop current oral antibiotics. From the 28 on iv antibiotics, 6 (21%) could stop, 18 (64%) could switch to an oral antibiotic and 4 (14%) should remain on iv antibiotics. In addition, of the 209 patients who were not suitable for discharge, 27 on oral therapy (13%) and 16 on iv+oral therapy (8%) were considered suitable for cessation of therapy, and a further 25 patients were assessed as suitable to be switched from iv+oral therapy to oral therapy only. In total, 150 (51%) of the 291 patients assessed were considered suitable for some form of policy change. Table 3 summarizes the costs or cost savings arising if these recommendations had been implemented. A total of 494 inpatient days would have been saved at a potential cost saving of £186731. Additional savings that would have been made included £446 saved by switching from an oral antibiotic to no antibiotic, £10 536 by switching from an iv antibiotic to no antibiotic and £9233 by switching from iv to oral therapy. Additional costs would have been incurred relating to the assessment (£2468), community support costs (£6227) and OPAT (£5616). As a result, net potential savings would be £192 635 in total or £662 (95% CI: £393, £930) per patient assessed.
Sensitivity analyses
Lengths of stay are frequently skewed, with a small number of patients incurring long lengths of stay and therefore contributing disproportionately to overall bed-days and, in this instance, possible bed-day savings. Excluding eight patients with the highest potentially avoidable inpatient stays (.15 days), mean savings would fall to £363 per patient assessed but remain highly significant (95% CI: £261, £465) ( Table 4) .
The estimated cost of providing an OPAT service-£151.80 per person per day-is taken from a large, detailed and recent UK study; however, it is possible that support costs for iv antibiotic users in the community could be higher or lower than the figure used, if such services were configured differently or depending on patient characteristics. Increasing or reducing this figure by 25% has little effect on the overall results: if 25% lower, the net saving per person would rise from £662 to £667; if 25% higher, the net saving person would fall to £657.
It is possible that in practice a lower proportion of patients than in this study are identified as suitable for early discharge. Halving the numbers identified as suitable from 82 to 41 would have the effect of halving the identified length of stay savings, reducing therapy switching savings and potentially doubling the costs of the community support and OPAT (if these are essentially fixed costs), but would still yield a net saving of £260 per patient.
It is also possible that earlier discharge may result in an increased readmission rate. If 10% of patients identified for early discharge were readmitted for an average of 5 days to a general medical ward, the saving per patient would fall from £662 to £529.
Discussion
This service evaluation aimed to illustrate the potential clinical and economic impact of implementing a formal antibiotic review and early discharge programme across a number of different hospitals, specialties and patient characteristics. The assessment indicated that 28% of patients assessed were considered to be potentially suitable for early discharge, with a further 23% of patients considered not suitable for early Antibiotic management and economics of early discharge 2299 JAC discharge but suitable for some form of change to their current antibiotic treatment altered. A companion paper 4 gives fuller details and discussion of the assessment procedures used, and places these in the wider context of antibiotic stewardship.
Our economic analysis found that careful assessment of antibiotic use in acute wards has the potential to reduce the use and cost of antibiotics, and length of stay. The added costs of assessment and out-of-hospital support services would offset a small proportion of these potential savings. Most of the savings are related to potential reductions in lengths of stay as a result of earlier discharge.
These savings should be viewed as opportunity costs rather than cash savings, i.e. each inpatient day saved can then be used for other purposes (such as reducing waiting times) or, in Figure 1 . Flow diagram of patients through service evaluation. Gray et al.
the longer term, could be realized in actual savings in the form of fewer beds. It is clear from our analysis that most of the savings identified would accrue to hospitals while additional costs are mainly incurred by community services; this argues a need for good integration of service and budgets.
It is possible that early discharge schemes may shift costs from the formal healthcare sector onto informal carers, such as family and friends. Very few studies have addressed this issue in the context of early discharge or domiciliary care schemes 11 and no information on this was collected in the present study, but data could usefully be collected in future research studies.
Future full evaluations of such interventions should also consider health outcomes such as morbidity, quality of life and mortality as well as costs, within the framework of an incremental cost-effectiveness or cost-utility study.
Increasing recognition of the potential gains from improving inpatient antibiotic prescribing has led to the development of explicit recommendations, such as the use of an antimicrobial selfassessment toolkit 12 and of antibiotic prescribing bundles. 13 However, the fact that studies, audits and official reports 3 continue to identify considerable scope for improvement suggests that either the evidence or the incentives to take action are not sufficiently compelling to induce change. A more explicit and quantified focus on the potential cost savings from formal antibiotic review, in the context of more cash-constrained healthcare systems for the foreseeable future, may stimulate interest in such initiatives.
This study was a service evaluation and did not adhere to a formal research design, such as a randomized trial, casecontrol study or before-after comparison. In consequence, the results may be subject to a number of biases and limitations. Randomized studies are now needed to test these results.
However, the evaluation does provide useful descriptive information for a sample of individual patients across a range of different practice settings, and the economic analysis has generated data that may be helpful when designing an intervention study, including the likely magnitude and variance of potential costs and savings. Antibiotic management and economics of early discharge
